Cost-effectiveness of sequenced treatment of rheumatoid arthritis with targeted immune modulators

References

• Helmick CG, Felson DT, Lawrence RC, et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I. Arthritis Rheum 2008;58:15-25
   PubMed Web of Science ®Google Scholar
• Pincus T, Callahan LF, Sale WG, et al. Severe functional declines, work disability, and increased mortality in seventy-five rheumatoid arthritis patients studied over nine years. Arthritis Rheum 1984;27:864-72
   PubMed Web of Science ®Google Scholar
• Singh JA, Saag KG, Bridges SL Jr, et al. 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheum 2016;68:1-26
   PubMed Web of Science ®Google Scholar
• Huizinga TW, Pincus T. In the clinic. Rheumatoid arthritis. Ann Intern Med 2010;153:ITC1-1-ITC1-15; quiz ITC1-16
   Web of Science ®Google Scholar
• Gibofsky A. Overview of epidemiology, pathophysiology, and diagnosis of rheumatoid arthritis. Am J Manag Care 2012;18:S295-S302
   PubMedGoogle Scholar
• Lawrence RC, Felson DT, Helmick CG, et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States: part II. Arthritis Rheum 2008;58:26-35
   PubMed Web of Science ®Google Scholar
• Lawrence RC, Helmick CG, Arnett FC, et al. Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis Rheum 1998;41:778-99
   PubMed Web of Science ®Google Scholar
• US Department of Labor Bureau of Labor Statistics. Consumer Price Index-All Urban Consumers. Washington, DC: US Department of Labor Bureau of Labor Statistics 2016. http://data.bls.gov/cgi-bin/surveymost?cu. Accessed February 28, 2017
   Google Scholar
• Birnbaum H, Pike C, Kaufman R, et al. Societal cost of rheumatoid arthritis patients in the US. Curr Med Res Opin 2010;26:77-90
   PubMed Web of Science ®Google Scholar
• Lundkvist J, Kastang F, Kobelt G. The burden of rheumatoid arthritis and access to treatment: health burden and costs. Eur J Health Econ 2008;8(suppl 2):S49-S60
   PubMed Web of Science ®Google Scholar
• Yazdany J, Dudley RA, Chen R, et al. Coverage for high-cost specialty drugs for rheumatoid arthritis in Medicare Part D. Arthritis Rheum 2015;67:1474-80
   PubMed Web of Science ®Google Scholar
• Gunnarsson C, Chen J, Rizzo JA, et al. The employee absenteeism costs of rheumatoid arthritis: evidence from US national survey data. J Occup Environ Med 2015;57:635-42
   PubMed Web of Science ®Google Scholar
• Eriksson JK, Johansson K, Askling J, et al. Costs for hospital care, drugs and lost work days in incident and prevalent rheumatoid arthritis: how large, and how are they distributed? Ann Rheum Dis 2015;74:648-54
   PubMed Web of Science ®Google Scholar
• Ohinmaa AE, Thanh NX, Barnabe C, et al. Canadian estimates of health care utilization costs for rheumatoid arthritis patients with and without therapy with biologic agents. Arthritis Care Res (Hoboken) 2014;66:1319-27
   PubMed Web of Science ®Google Scholar
• Ma VY, Chan L, Carruthers KJ. Incidence, prevalence, costs, and impact on disability of common conditions requiring rehabilitation in the United States: stroke, spinal cord injury, traumatic brain injury, multiple sclerosis, osteoarthritis, rheumatoid arthritis, limb loss, and back pain. Arch Phys Med Rehabil 2014;95:986-95
   PubMed Web of Science ®Google Scholar
• Curtis JR, Schabert VF, Harrison DJ, et al. Estimating effectiveness and cost of biologics for rheumatoid arthritis: application of a validated algorithm to commercial insurance claims. Clin Ther 2014;36:996-1004
   PubMed Web of Science ®Google Scholar
• Chevreul K, Haour G, Lucier S, et al. Evolution of direct costs in the first years of rheumatoid arthritis: impact of early versus late biologic initiation–an economic analysis based on the ESPOIR cohort. PLoS One 2014;9:e97077
   PubMed Web of Science ®Google Scholar
• Wolfe F, Allaire S, Michaud K. The prevalence and incidence of work disability in rheumatoid arthritis, and the effect of anti-tumor necrosis factor on work disability. J Rheumatol 2007;34:2211-7
   PubMed Web of Science ®Google Scholar
• van Nies JA, de Jong Z, van der Helm-van Mil AH, et al. Improved treatment strategies reduce the increased mortality risk in early RA patients. Rheumatology (Oxford) 2010;49:2210-6
   PubMed Web of Science ®Google Scholar
• Strand V, Greenberg JD, Griffith J, et al. Impact of treatment with biologic agents on the use of mechanical devices among rheumatoid arthritis patients in a large US patient registry. Arthritis Care Res (Hoboken) 2016;68:914-21
   PubMed Web of Science ®Google Scholar
• Smolen JS, Han C, van der Heijde D, et al. Infliximab treatment maintains employability in patients with early rheumatoid arthritis. Arthritis Rheum 2006;54:716-22
   PubMed Web of Science ®Google Scholar
• van Vollenhoven RF, Ernestam S, Geborek P, et al. Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial. Lancet 2009;374:459-66
   PubMed Web of Science ®Google Scholar
• Curtis JR, Zhang J, Xie F, et al. Use of oral and subcutaneous methotrexate in rheumatoid arthritis patients in the United States. Arthritis Care Res (Hoboken) 2014;66:1604-11
   PubMed Web of Science ®Google Scholar
• Bays AM, Gardner G. Pharmacologic therapies for rheumatologic and autoimmune conditions. Med Clin North Am 2016;100:719-31
   PubMed Web of Science ®Google Scholar
• Souto A, Maneiro JR, Gomez-Reino JJ. Rate of discontinuation and drug survival of biologic therapies in rheumatoid arthritis: a systematic review and meta-analysis of drug registries and health care databases. Rheumatology (Oxford) 2016;55:523-34
   PubMed Web of Science ®Google Scholar
• Vera-Llonch M, Massarotti E, Wolfe F, et al. Cost-effectiveness of abatacept in patients with moderately to severely active rheumatoid arthritis and inadequate response to methotrexate. Rheumatology (Oxford) 2008;47:535-41
   PubMed Web of Science ®Google Scholar
• Yuan Y, Trivedi D, Maclean R, et al. Indirect cost-effectiveness analyses of abatacept and rituximab in patients with moderate-to-severe rheumatoid arthritis in the United States. J Med Econ 2010;13:33-41
   PubMedGoogle Scholar
• Wong JB, Singh G, Kavanaugh A. Estimating the cost-effectiveness of 54 weeks of infliximab for rheumatoid arthritis. Am J Med 2002;113:400-8
   PubMed Web of Science ®Google Scholar
• Rubenfire A. Rheumatoid arthritis drug prices on the rise; Chicago, IL: Modern Healthcare 2016. http://www.modernhealthcare.com/article/20160401/NEWS/160409993. Accessed January 13, 2017
   Google Scholar
• Stevenson M, Archer R, Tosh J, et al. Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation. Health Technol Assess 2016;20:1-610
   Web of Science ®Google Scholar
• Braithwaite RS, Meltzer DO, King JT, Jr., et al. What does the value of modern medicine say about the $50,000 per quality-adjusted life-year decision rule? Med Care 2008;46:349-56
   PubMed Web of Science ®Google Scholar
• Weinstein MC. How much are Americans willing to pay for a quality-adjusted life year? Med Care 2008;46:343-5
   PubMed Web of Science ®Google Scholar
• Neumann PJ, Cohen JT, Weinstein MC. Updating cost-effectiveness—the curious resilience of the $50,000-per-QALY threshold. N Engl J Med 2014;371:796-7
   PubMed Web of Science ®Google Scholar
• World Health Organization. Report of the Commission on Macroeconomics and Health: Macroeconomics and Health: Investing in health for economic development. Geneva, Switzerland: WHO; 2001. http://apps.who.int/iris/bitstream/10665/42435/1/924154550X.pdf. Accessed February 10, 2017
   Google Scholar
• Amgen Inc., Precision Health Economics. RA Microsimulation: Cost-effectiveness of sequenced treatment of rheumatoid arthritis with targeted immune modulators. Thousand Oaks, CA: Amgen Inc. 2017. http://www.economicmodelforra.com. Accessed March 8, 2017
   Google Scholar
• R Core Team. R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing, 2016. https://www.r-project.org/. Accessed January 13, 2017
   Google Scholar
• Wolfe F, Michaud K. The loss of health status in rheumatoid arthritis and the effect of biologic therapy: a longitudinal observational study. Arthritis Res Ther 2010;12:R35
   PubMed Web of Science ®Google Scholar
• Michaud K, Wallenstein G, Wolfe F. Treatment and nontreatment predictors of health assessment questionnaire disability progression in rheumatoid arthritis: a longitudinal study of 18,485 patients. Arthritis Care Res (Hoboken) 2011;63:366-72
   PubMed Web of Science ®Google Scholar
• West S. Rheumatology secrets, 3rd ed. Philadelphia, PA: Mosby, 2014
   Google Scholar
• Smolen JS, Aletaha D. Rheumatoid arthritis therapy reappraisal: strategies, opportunities and challenges. Nat Rev Rheumatol 2015;11:276-89
   PubMed Web of Science ®Google Scholar
• Strand V, Williams S, Miller PSJ, et al. OP0064 discontinuation of biologic therapy in rheumatoid arthritis (RA): analysis from the Consortium of Rheumatology Researchers of North America (CORRONA) database. Ann Rheum Dis 2013;72:A71-A72
   Web of Science ®Google Scholar
• Singh JA, Wells GA, Christensen R, et al. SAT0461 adverse effects of biologics: a network meta-analysis and cochrane overview. Ann Rheum Dis 2013;71:628
   Web of Science ®Google Scholar
• Hernández Alava M, Wailoo AJ, Ara R. Tails from the peak district: adjusted limited dependent variable mixture models of EQ-5D questionnaire health state utility values. Value Health 2012;15:550-61
   PubMed Web of Science ®Google Scholar
• Hernández Alava M, Wailoo A, Wolfe F, et al. The relationship between EQ-5D, HAQ and pain in patients with rheumatoid arthritis. Rheumatology (Oxford) 2013;52:944-50
   PubMed Web of Science ®Google Scholar
• Hernández Alava M, Wailoo A, Wolfe F, et al. A comparison of direct and indirect methods for the estimation of health utilities from clinical outcomes. Med Decis Making 2014;34:919-30
   PubMed Web of Science ®Google Scholar
• Oppong R, Kaambwa B, Nuttall J, et al. The impact of using different tariffs to value EQ-5D health state descriptions: an example from a study of acute cough/lower respiratory tract infections in seven countries. Eur J Health Econ 2013;14:197-209
   PubMed Web of Science ®Google Scholar
• Arias E. United States life tables, 2011. National Vital Statistics Reports. Hyattsville, MD: National Center for Health Statistics; 2015
   Google Scholar
• Wolfe F, Michaud K, Gefeller O, et al. Predicting mortality in patients with rheumatoid arthritis. Arthritis Rheum 2003;48:1530-42
   PubMed Web of Science ®Google Scholar
• Michaud K, Vera-Llonch M, Oster G. Mortality risk by functional status and health-related quality of life in patients with rheumatoid arthritis. J Rheumatol 2012;39:54-9
   PubMed Web of Science ®Google Scholar
• SSRHealth. US Brand Rx Net Price. Access-restricted document, Stamford, CT: SSRHealth 2016
   Google Scholar
• Carlson JJ, Ogale S, Dejonckheere F, et al. Economic evaluation of tocilizumab monotherapy compared to adalimumab monotherapy in the treatment of severe active rheumatoid arthritis. Value Health 2015;18:173-9
   PubMed Web of Science ®Google Scholar
• Centers for Medicare & Medicaid Services. FY 2016 Final Rule, Correction Notice and Consolidated Appropriations Act of 2016 Tables, Baltimore, MD: Centers for Medicare & Medicaid Services 2016. https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/FY2016-IPPS-Final-Rule-Home-Page-Items/FY2016-IPPS-Final-Rule-Tables.html?DLPage=1&DLEntries=10&DLSort=0&DLSortDir=ascending. Accessed February 15, 2017
   Google Scholar
• Wolfe F, Michaud K, Choi HK, et al. Household income and earnings losses among 6,396 persons with rheumatoid arthritis. J Rheumatol 2005;32:1875-83
   PubMed Web of Science ®Google Scholar
• Curtis JR, Jain A, Askling J, et al. A comparison of patient characteristics and outcomes in selected European and US rheumatoid arthritis registries. Semin Arthritis Rheum 2010;40:2-14. e1
   PubMed Web of Science ®Google Scholar
• National Center for Health Statistics, Centers for Disease Control and Prevention. Body Measurements, Atlanta, GA: Centers for Disease Control and Prevention 2016. https://www.cdc.gov/nchs/fastats/body-measurements.htm. Accessed February 2, 2017
   Google Scholar
• Moots R, Haraoui B, Matucci-Cerinic M, et al. Differences in biologic dose-escalation, non-biologic and steroid intensification among three anti-TNF agents: evidence from clinical practice. Clin Exp Rheumatol 2010;29:26-34
   Web of Science ®Google Scholar
• BlueCross BlueShield. A study of cost variations for knee and hip replacement surgeries in the U.S., Chicago, IL and Washington, DC: BlueCross Blue Shield 2015. https://www.bcbs.com/about-us/capabilities-initiatives/health-america/health-of-america-report/study-cost-variations. Accessed February 7, 2017
   Google Scholar
• Claxton L, Jenks M, Taylor M, et al. An economic evaluation of tofacitinib treatment in rheumatoid arthritis: modeling of the cost of treatment strategies in the United States. J Manag Care Spec Pharm 2016;22:1088-102
   PubMedGoogle Scholar
• Nikiphorou E, Norton S, Young A, et al. Association between rheumatoid arthritis disease activity, progression of functional limitation and long-term risk of orthopaedic surgery: combined analysis of two prospective cohorts supports EULAR treat to target DAS thresholds. Ann Rheum Dis 2016;75:2080-6
   PubMed Web of Science ®Google Scholar
• Dubois RW. Cost-effectiveness thresholds in the USA: are they coming? Are they already here? J Comp Eff Res 2016;5:9-11
   PubMed Web of Science ®Google Scholar
• Kahlenberg JM, Fox DA. Advances in the medical treatment of rheumatoid arthritis. Hand Clin 2011;27:11-20
   PubMed Web of Science ®Google Scholar
• Wailoo AJ, Bansback N, Brennan A, et al. Biologic drugs for rheumatoid arthritis in the Medicare program: a cost-effectiveness analysis. Arthritis Rheum 2008;58:939-46
   PubMed Web of Science ®Google Scholar
• Carpenter L, Nikiphorou E, Sharpe R, et al. Have radiographic progression rates in early rheumatoid arthritis changed? A systematic review and meta-analysis of long-term cohorts. Rheumatology (Oxford) 2016; [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Shourt CA, Crowson CS, Gabriel SE, et al. Orthopedic surgery among patients with rheumatoid arthritis 1980–2007: a population-based study focused on surgery rates, sex, and mortality. J Rheumatol 2012;39:481-5
   PubMed Web of Science ®Google Scholar
• Wolfe F, Zwillich SH. The long-term outcomes of rheumatoid arthritis: a 23-year prospective, longitudinal study of total joint replacement and its predictors in 1,600 patients with rheumatoid arthritis. Arthritis Rheum 1998;41:1072-82
   PubMed Web of Science ®Google Scholar
• Tosh J, Brennan A, Wailoo A, et al. The Sheffield rheumatoid arthritis health economic model. Rheumatology (Oxford) 2011;50(Suppl 4):iv26-31
   PubMed Web of Science ®Google Scholar